Cogent Biosciences Beheer
Beheer criteriumcontroles 2/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Andy Robbins
Algemeen directeur
US$7.9m
Totale compensatie
Percentage CEO-salaris | 8.3% |
Dienstverband CEO | 4.1yrs |
Eigendom CEO | n/a |
Management gemiddelde ambtstermijn | 3.8yrs |
Gemiddelde ambtstermijn bestuur | 4.3yrs |
Recente managementupdates
Recent updates
Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans
Sep 04Cogent Biosciences: Inflection Year Directly Ahead
Jun 23Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans
May 22Cogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data Catalyst
Feb 14Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Nov 27Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?
Jun 20Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Mar 05Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Nov 18Cogent Biosciences: What's Ahead
Sep 13Cogent Biosciences: APEX Data Was Interesting, But We Need More
Jun 26Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?
Jun 10Cogent Biosciences names new chief legal officer
May 03What You Need To Know About Cogent Biosciences, Inc.'s (NASDAQ:COGT) Investor Composition
Mar 17Cogent Biosciences gets Piper Sandler nod on Kiq acquisition
Dec 23Cogent Biosciences prices upsized $100M equity offering
Dec 02Cogent Bio launches $60M equity offering, shares down 7%
Nov 30Cogent Bio reports data from PLX9486 combo trial in GIST patients
Nov 18Cogent Biosciences EPS misses by $4.91
Nov 09Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$242m |
Jun 30 2024 | n/a | n/a | -US$227m |
Mar 31 2024 | n/a | n/a | -US$212m |
Dec 31 2023 | US$8m | US$656k | -US$192m |
Sep 30 2023 | n/a | n/a | -US$178m |
Jun 30 2023 | n/a | n/a | -US$157m |
Mar 31 2023 | n/a | n/a | -US$148m |
Dec 31 2022 | US$4m | US$624k | -US$140m |
Sep 30 2022 | n/a | n/a | -US$126m |
Jun 30 2022 | n/a | n/a | -US$110m |
Mar 31 2022 | n/a | n/a | -US$91m |
Dec 31 2021 | US$3m | US$593k | -US$72m |
Sep 30 2021 | n/a | n/a | -US$163m |
Jun 30 2021 | n/a | n/a | -US$194m |
Mar 31 2021 | n/a | n/a | -US$185m |
Dec 31 2020 | US$18m | US$102k | -US$179m |
Compensatie versus markt: De totale vergoeding ($USD 7.90M ) Andy } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.19M ).
Compensatie versus inkomsten: De vergoeding van Andy is gestegen terwijl het bedrijf verliesgevend is.
CEO
Andy Robbins (48 yo)
4.1yrs
Tenure
US$7,898,772
Compensatie
Mr. Andrew R. Robbins, also known as Andy, M.B.A., serves as Chief Executive Officer, President and Director at of Cogent Biosciences, Inc. (formerly Unum Therapeutics Inc.) since October 23, 2020. He was...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
President | 4.1yrs | US$7.90m | geen gegevens | |
Chief Scientific Officer | 3.6yrs | US$2.98m | 0% $ 0 | |
Chief Medical Officer | 5.4yrs | US$3.00m | 0.0012% $ 11.6k | |
CFO & Principal Accounting Officer | 4.3yrs | US$2.14m | geen gegevens | |
Chief Technology Officer | 4yrs | geen gegevens | geen gegevens | |
Senior Director of Investor Relations | no data | geen gegevens | geen gegevens | |
Chief Legal Officer & Corporate Secretary | 3.5yrs | geen gegevens | geen gegevens | |
Chief People Officer | no data | geen gegevens | geen gegevens | |
Senior VP of Medical Affairs & Chief Patient Officer | no data | geen gegevens | geen gegevens | |
Senior Vice President of Chemistry | no data | geen gegevens | geen gegevens | |
VP & Head of Clinical Development | 2yrs | geen gegevens | geen gegevens | |
Senior VP and Head of Regulatory & Pharmacovigilance | less than a year | geen gegevens | geen gegevens |
3.8yrs
Gemiddelde duur
48yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van COGT wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
President | 4.1yrs | US$7.90m | geen gegevens | |
Independent Director | 5.3yrs | US$345.49k | 0% $ 0 | |
Independent Director | 5.3yrs | US$336.69k | 0% $ 0 | |
Independent Director | 3.8yrs | US$345.80k | 0% $ 0 | |
Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Independent Director | 6.8yrs | US$340.37k | 0% $ 0 | |
Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Independent Director | 4.3yrs | US$341.36k | 0% $ 0 | |
Independent Chairman of the Board | 4.3yrs | US$364.55k | 0% $ 0 | |
Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | 1.8yrs | geen gegevens | geen gegevens |
4.3yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van COGT wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).